Treatment with metformin led to increased overall and disease-free survival in CRC diabetic patients [174,175], opposing cell cycle and growth, cancer stem cells and metastatic ability via mammalian target of rapamycin (mTOR) and PI3K/Akt pathway inhibition and AMPK activation [176]. This evidence concerns the gene MTOR and colorectal carcinoma.